The RRAGD Gene and Genetic Variants
At a Glance
Hypomagnesemia 7 is caused by a disease-causing change in the RRAGD gene that can disrupt kidney magnesium balance and affect the heart. Published cases show different patterns, so one variant cannot predict an individual outcome; genetic counseling and family monitoring are important.
The root cause of Hypomagnesemia 7 (ADKH-RRAGD) lies in a pathogenic variant within your genetic code, specifically in a gene called RRAGD. This gene provides the instructions for making a protein called RagD [1]. Understanding how this protein works—and how your specific variant changes its behavior—is key to managing your health.
How the RRAGD Gene Works
Every cell in your body needs to know when it has enough nutrients to grow and when it needs to conserve energy. The RagD protein acts like a biological “scout” or “recruiter” [2]. Its job is to sense when amino acids (the building blocks of protein) are available and then recruit a master controller called mTORC1 to a specific part of the cell called the lysosome [3]. Once there, mTORC1 can turn on the cell’s growth and energy-using machinery.
Current experimental disease models suggest that in people with this condition, the pathogenic variant in the RRAGD gene alters the RagD protein’s signaling. In laboratory studies, this is often observed as constitutive mTORC1 signaling—meaning the signaling pathway acts as if it is constantly turned on, even when it shouldn’t be [4][5]. This constant, misplaced activity is thought to disrupt the normal function of cells in the kidneys and the heart, leading to the symptoms of the disease [6].
Why Your Specific Variant Matters
Not all genetic changes in the RRAGD gene are the same. A confirmed pathogenic variant causes disease, whereas a Variant of Uncertain Significance (VUS) means there is not yet enough evidence to prove it causes health issues. A VUS should not be used as proof of the disease or for predictive family testing.
For pathogenic variants, the exact location and type of change (your HGVS designation) can offer observations based on published cases [1]. Because the disease is so rare, these are past observations, not guaranteed individual predictions:
- S76L, I221K, and P119R: In published cases, these variants have been associated with severe presentations. They were frequently reported alongside significant electrolyte imbalances and heart issues (dilated cardiomyopathy) starting in childhood, sometimes requiring a heart transplant [1][4].
- P119L: This variant was reported to involve kidney issues (like low magnesium and potassium) that became noticeable during the teenage years [1].
- P88L: In the literature, this variant has been linked to dilated cardiomyopathy that developed later in life, during adulthood [1].
- T97P: To date, this specific variant has been found in patients with kidney issues but was not reported with heart involvement in the cited cases [1]. However, because this condition is so rare, doctors still monitor these patients closely.
How the Condition is Inherited
This condition follows an autosomal dominant inheritance pattern [4]. This means:
- Autosomal: The gene is located on one of the numbered chromosomes, not the sex chromosomes (X or Y), so it affects males and females equally.
- Dominant: You only need one copy of the altered gene (from either parent) to have the condition.
De Novo vs. Inherited
In many cases of ADKH-RRAGD, the genetic change is de novo, meaning it happened for the first time in the patient and was not passed down from a parent [4]. However, it can also be inherited. If a person has the condition, there is a 50% chance they will pass the variant on to each of their children [4]. It is important to note that expression varies, meaning a child who inherits the variant may not have the exact same symptoms or severity as the parent.
Cascade Testing
Because the condition is dominant and symptoms can vary greatly—even among family members with the same variant—doctors recommend cascade testing [7]. This involves testing the biological parents and siblings of the diagnosed person to see if they also carry the variant. Finding the variant in a relative who doesn’t yet have symptoms allows doctors to begin monitoring their heart and kidneys early, which is vital for long-term health [1][8].
Common questions in this guide
How does a change in the RRAGD gene cause Hypomagnesemia 7?
How is RRAGD-related Hypomagnesemia 7 passed through families?
What is the difference between a pathogenic RRAGD variant and a VUS?
Can a specific RRAGD variant show whether I will develop cardiomyopathy?
Which relatives may need RRAGD genetic testing?
What does the HGVS code on my RRAGD genetic report mean?
Get notified when new evidence is published on hypomagnesemia 7, renal, with or without dilated cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
RRAGD-Associated Autosomal Dominant Kidney Hypomagnesemia with Cardiomyopathy: A Review on the Clinical Manifestations and Therapeutic Options.
Trepiccione F, Sambri I, Ruggiero B, et al.
Kidney & blood pressure research 2024; (49(1)):637-645 doi:10.1159/000539889.
PMID: 38901414 - 2
Rag GTPase in amino acid signaling.
Kim J, Kim E
Amino acids 2016; (48(4)):915-928 doi:10.1007/s00726-016-2171-x.
PMID: 26781224 - 3
Architecture of human Rag GTPase heterodimers and their complex with mTORC1.
Anandapadamanaban M, Masson GR, Perisic O, et al.
Science (New York, N.Y.) 2019; (366(6462)):203-210 doi:10.1126/science.aax3939.
PMID: 31601764 - 4
mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy.
Schlingmann KP, Jouret F, Shen K, et al.
Journal of the American Society of Nephrology : JASN 2021; (32(11)):2885-2899 doi:10.1681/ASN.2021030333.
PMID: 34607910 - 5
Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives.
Adella A, Jouret F, Madariaga L, et al.
Kidney international reports 2025; (10(10)):3640-3655 doi:10.1016/j.ekir.2025.07.035.
PMID: 41141537 - 6
RagD auto-activating mutations impair MiT/TFE activity in kidney tubulopathy and cardiomyopathy syndrome.
Sambri I, Ferniani M, Campostrini G, et al.
Nature communications 2023; (14(1)):2775 doi:10.1038/s41467-023-38428-2.
PMID: 37188688 - 7
Tips for Testing Adults With Suspected Genetic Kidney Disease.
Savige J
American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (83(6)):816-824 doi:10.1053/j.ajkd.2023.10.011.
PMID: 38147894 - 8
What patients want to know about genetic testing for kidney disease.
Savige J, Weinstock BA
Frontiers in medicine 2023; (10()):1201712 doi:10.3389/fmed.2023.1201712.
PMID: 37342499
This page explains RRAGD variants and inheritance in Hypomagnesemia 7 for informational purposes only and does not replace medical advice. A genetics professional, nephrologist, or cardiologist should interpret your results and recommend monitoring for you and your family.